The role of the gut microbiome in graft fibrosis after pediatric liver transplantationQin, T., Fu, J. & Verkade, H. J., 13-Sep-2020, In : HUMAN GENETICS. 16 p.
Research output: Contribution to journal › Review article › Academic › peer-review
Liver transplantation (LT) is a life-saving option for children with end-stage liver disease. However, about 50% of patients develop graft fibrosis in 1 year after LT, with normal liver function. Graft fibrosis may progress to cirrhosis, resulting in graft dysfunction and ultimately the need for re-transplantation. Previous studies have identified various risk factors for the post-LT fibrogenesis, however, to date, neither of the factors seems to fully explain the cause of graft fibrosis. Recently, evidence has accumulated on the important role of the gut microbiome in outcomes after solid organ transplantation. As an altered microbiome is present in pediatric patients with end-stage liver diseases, we hypothesize that the persisting alterations in microbial composition or function contribute to the development of graft fibrosis, for example by bacteria translocation due to increased intestinal permeability, imbalanced bile acids metabolism, and/or decreased production of short-chain fatty acids (SCFAs). Subsequently, an immune response can be activated in the graft, together with the stimulation of fibrogenesis. Here we review current knowledge about the potential mechanisms by which alterations in microbial composition or function may lead to graft fibrosis in pediatric LT and we provide prospective views on the efficacy of gut microbiome manipulation as a therapeutic target to alleviate the graft fibrosis and to improve long-term survival after LT.
|Number of pages||16|
|Publication status||Published - 13-Sep-2020|
- DONOR-SPECIFIC ANTIBODIES, INTESTINAL MICROBIOTA, AKKERMANSIA-MUCINIPHILA, CELLULAR REJECTION, ALLOGRAFT FIBROSIS, MOUSE MODELS, DISEASE, INJURY, LACTOBACILLUS, RECIPIENTS